Kenneth Sundberg

Anison Therapeutics aims at building a portfolio of technologies targeting the Human Papillomavirus(HPV)-mediated diseases. The first steps are taken by dedicated efforts towards developing and commercializing a _topical cream (containing a HPV targeting compound) that addresses unmet medical needs for genital warts, with preclinical studies p_rojected to start during the first half of 2023. Longer term, the company will also focus on the treatment of genital pre-cancerous lesions and other HPV-associated warts, including common and foot(plantar) warts, thus becoming a successful company with solid sales growth and a strong pipeline of new products to be introduced to the roughly >$8Bn market.